ERBB2 and breast cancer: The SOLAR-1 trial evaluated a PI3Kα-specific inhibitor, alpelisib, and reported a prolonged PFS among patients harboring PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancers who had previously received endocrine therapy [12].